The use of selective aldosterone antagonists.
Mineralocorticoid hormones, specifically aldosterone, have been shown to be increasingly important in the development and maintenance of cardiovascular disorders, particularly hypertension and congestive heart failure. The use of the mineralocorticoid receptor blocker, spironolactone, has been fraught with side effects, largely related to the poor specificity of this agent. Eplerenone, a new and more specific mineralocorticoid receptor blocker with little effect on sex-hormone receptors, has offered an alternative approach. Many studies in hypertension as well as a major and compelling study in congestive heart failure have documented the efficacy and specificity of eplerenone with a minimum of side effects. The major findings with this new agent are presented herein.
Weinberger
Myron H
MH
Indiana University Medical Center, 541 Clinical Drive, Room 423, Indianapolis, IN 46202, USA. mweinbe@IUPUI.edu
D000368:Aged; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000077545:Eplerenone; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D013148:Spironolactone / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D016019:Survival Analysis; D016896:Treatment Outcome
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone